<DOC>
	<DOCNO>NCT02813473</DOCNO>
	<brief_summary>The SYNTAX III Revolution trial randomize diagnostic research study investigate use CT scan angiogram heart help doctor decide method best improve blood supply heart patient complex coronary artery disease . Each patient undergo angiogram CT scan per standard care . The randomization strategy study patient two team doctor , so-called `` Heart Teams '' , randomize : first round , team 1 ass angiogram , team 2 ass CT scan . Then make decision treatment would best treat complex coronary artery disease . In second round , team see image method see first round , make decision . The final decision clinical treatment strategy sole discretion Heart Team criterion describe SYNTAXIII Revolution protocol lead influence final decision . Hypothesis : Determination best treatment strategy coronary artery disease base CT scan result similar decision base invasive coronary angiography .</brief_summary>
	<brief_title>SYNTAX III REVOLUTION Trial : A Randomized Study Investigating Use CT Scan Angiography Heart Help Doctors Decide Which Method Best Improve Blood Supply Heart Patients With Complex Coronary Artery Disease</brief_title>
	<detailed_description>The SYNTAX III REVOLUTION Trial multicenter , all-comers trial ( either isolate unprotected left-main 3-vessel disease without left-main disease candidate either CABG PCI treatment ) . In SYNTAXIII REVOLUTION diagnostic coronary angiography diagnostic coronary Multislice CT perform allow Heart Team ass optimal revascularization strategy . In normal hospital set angiography consider standard care . The multislice CT already also part diagnosis discretion physician . After images modality available , patient long participate trial . Next step randomization Heart Team A Heart B sequence availability image , i.e . randomize whether Heart Team A review angiography first multislice CT , automatically , Heart B modality . The Heart Teams need make decision surgical percutaneous treatment accord either conventional angiography multislice CT angiography assessment . In addition , incremental value FFRCT decision make Heart Team arm allocate primarily assessment MSCT ( CT first algorithm ) secondary endpoint . No intervention patient 's treatment take place</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>1 . Patients least 1 stenosis ( angiographic , visually determine de novo lesion â‰¥50 % DS ) 3 major epicardial territory ( LAD and/or side branch , CX and/or side branch , RCA and/or side branch ) supply viable myocardium without leave main involvement ; 2 . Patients hypoplastic RCA absence descend posterior presence lesion LAD CX territory may include trial 3VD equivalent ; 3 . Vessel size least 1.5 mm diameter visually assess diagnostic angiogram ; 4 . Patients chronic stable angina stabilize acute coronary syndrome ( inclusion criterion SYNTAX I study ) : stable ( Canadian Cardiovascular Society Class 1 , 2 , 3 4 ) angina pectoris ; unstable ( Braunwald class IB , IC , IIB , IIC , IIIB , IIIC ) angina pectoris ischemia normal cardiac enzyme value prior enrollment ; patient atypical chest pain asymptomatic provide myocardial ischemia ( e.g . treadmill exercise test , radionuclide scintigraphy , stress echocardiography ) ; 5 . All anatomical SYNTAX Scores eligible ; 6 . Patient amenable MSCT coronary angiography ( e.g . claustrophobia , high heartrate amenable betablockers , poor renal function , etc. , discretion investigator ) ; 7 . Patient informed nature study agree provision provide write informed consent approve Ethical Committee respective clinical site ; 1 . Under age 18 year ; 2 . Unable give Informed Consent ; 3 . Known pregnancy time enrolment . Female childbearing potential ( last menstruation within last 12 month ) , take adequate contraceptive . Female breastfeeding time enrolment ; 4 . Prior PCI CABG ; history coronary stent implantation ; 5 . Evidence evolve ongoing acute myocardial infarction ( AMI ) ECG and/or elevate cardiac biomarkers ( accord local standard hospital practice ) return within normal limit time enrollment ; 6 . Concomitant cardiac valve disease require surgical therapy ( reconstruction replacement ) ; 7 . Single twovessel disease ( time Heart Team consensus ) ; 8 . Atrial fibrillation significant arrhythmia ; 9 . Known allergy iodinated contrast ; 10 . A Body Mass Index ( BMI ) 35 great ; 11 . Participation another trial investigational drug device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>SYNTAX Score II</keyword>
	<keyword>Multi Slice Computed Tomography</keyword>
	<keyword>MSCT</keyword>
	<keyword>Heart Team</keyword>
	<keyword>Fractional Flow Reserve Computed Tomography</keyword>
	<keyword>FFR</keyword>
	<keyword>FFR MSCT</keyword>
	<keyword>PCI</keyword>
	<keyword>CABG</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Coronary Artery Bypass Graft</keyword>
</DOC>